Patients in clinical remission
A clinical descriptor referring to patient populations who have achieved a state of disease control across various chronic conditions.
"Patients in clinical remission" is not a named individual, company, or organization. It is a widely used medical and research descriptor applied across multiple disease areas — including inflammatory bowel disease, rheumatoid arthritis, severe asthma, and juvenile idiopathic arthritis — to denote a subgroup of patients who have achieved a measurable reduction or absence of active disease symptoms.
Clinical remission is typically assessed using validated indices such as the CDAI (Crohn's Disease Activity Index), UCDAI, or DAS28, and is a standard endpoint in clinical trials and real-world evidence studies. The term defines a patient population subgroup rather than any discrete entity with a mission, leadership, or operational structure.
Because this phrase functions purely as a clinical classification, no B2B profile, organizational background, or entity-specific information can be accurately attributed to it. Any innovation relevant to this population would sit within the broader healthcare, pharmaceuticals, or clinical research sectors serving chronic disease management.